Sign in
Taking people in South KoreaPhase 2

Tests HD-6277 doses against placebo in adults with type 2 diabetes

Tests HD-6277 doses against placebo in adults with type 2 diabetes.

Key facts

Who runs it
Hyundai Pharm
Where
Seoul, South KoreaSee the site
Trial code
Registry title
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Status
Recruiting
Phase
Phase 2
People taking part
160 people, planned
Started
12 Dec 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HD-6277 100mg
  • HD-6277 50mg
  • HD-6277 25mg
  • Placebo
Record updated
13 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone.

Age
19 Years to 75 Years
Sex
All sexes can join.
Disease stage
Type 2 diabetes (T2DM) with HbA1c between 7.0% (53 mmol/mol) and 10.0% (86 mmol/mol) (inclusive).
Earlier treatment
Must have used diet and exercise alone for at least 8 weeks before screening.
Biomarker or test result
HbA1c between 7.0% (53 mmol/mol) and 10.0% (86 mmol/mol) (inclusive).

Main reasons for not taking part

  • Type 1 diabetes or another immune-mediated diabetes syndrome
  • BMI above 40 kg/m2
  • C-peptide below 0.5ng/mL

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening

Who cannot take part

  • Type 1 diabetes or another immune-mediated diabetes syndrome
  • BMI: > 40 kg/m2
  • C-peptide: < 0.5ng/mL

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 75 years old?

Where in South Korea

  • Korea University Anam HospitalSeoul, South KoreaContact: Sin-Gon Kim, PhDTaking people

About the trial

What the trial wants to find out

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

The 4 groups in the trial

  • HD-6277 100mg tabTreatment being tested

    Oral tablet

    Treatment: HD-6277 100mg

  • HD-6277 50mg tabTreatment being tested

    Oral tablet

    Treatment: HD-6277 50mg

  • HD-6277 25mg tabTreatment being tested

    Oral tablet

    Treatment: HD-6277 25mg

  • PlaceboPlacebo, for comparison

    Oral tablet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Plain-language title
Tests HD-6277 doses against placebo in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06647550, who can take part
Record updated
13 December 2024